Hoofddorp, The Netherlands, 6 June 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced that the annual general meeting followed all recommendations of the Company.
The minutes of the annual general meeting of the Company is available at https://www.igeapharma.nl/category/information-for-shareholders/
IGEA is a health-tech group focused on measure and control of identified factors related to life-threatening diseases. IGEA developed ‘ALZ-1’, a test kit to measure non ceruloplasmin bound copper (generally defined as “free” copper) in the bloodstream. “Free” copper is a risk factor associated with Alzheimer’s (AD) and diabetes type II (DBT2). Monitoring and normalizing “free” copper can contribute to reduce the risk of AD and DBT2 respectively.
IGEA is listed on the SIX Swiss Exchange under the ticker ‘IGPH’ and is headquartered in Hoofddorp, the Netherlands. The Group’s principal place of business is in the US.
For further information, please visit the IGEA website at https://www.igeapharma.nl/
IGEA Pharma N.V. Investor Relations: https://www.igeapharma.nl/investors-relations/
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA.
The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments, except as may be required by law.
IGEA Pharma N.V.
Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands
+31 23 568 94 94